LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

Core Viewpoint - LIR Life Sciences Corp. announced positive interim results from a comparative mouse study on a novel semaglutide/CPP topical formulation, indicating its potential effectiveness in reducing blood glucose levels [1] Group 1: Study Results - The interim analysis showed that animals treated with the semaglutide/CPP formulation had reduced blood glucose levels following an oral glucose challenge compared to untreated controls, suggesting pharmacologically meaningful activity [1]